Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1071-1080 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|January 13, 2010
Antibodies to watch in 2010Janice M Reichert
Mabs|January 13, 2010
Production of therapeutic antibodies with controlled fucosylationNaoko Yamane-Ohnuki, Mitsuo Satoh
Mabs|January 13, 2010
Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptorsYin Luo, Zhaojiang Lu, Stephen W Raso, et al.
Mabs|January 13, 2010
Preclinical development of monoclonal antibodies: considerations for the use of non-human primatesKathryn Chapman, Nick Pullen, Lee Coney, et al.
Mabs|January 13, 2010
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemiaMay Kung Sutherland, Changpu Yu, Timothy S Lewis, et al.
Mabs|January 13, 2010
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41Donna L Montgomery, Ying-Jie Wang, Renee Hrin, et al.
Mabs|January 14, 2010
Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peakXiaoying Nancy Chen, Mary Nguyen, Fred Jacobson, et al.
Mabs|January 14, 2010
Probabilities of success for antibody therapeuticsJanice M Reichert
Mabs|January 14, 2010
Antibody-maytansinoid conjugates for the treatment of myelomaRobert J Lutz, Kathleen R Whiteman
Mabs|January 14, 2010
Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1Kevin W McCabe
Pageof 184

Showing results (1071-1080 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|January 13, 2010
Antibodies to watch in 2010Janice M Reichert
Mabs|January 13, 2010
Production of therapeutic antibodies with controlled fucosylationNaoko Yamane-Ohnuki, Mitsuo Satoh
Mabs|January 13, 2010
Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptorsYin Luo, Zhaojiang Lu, Stephen W Raso, et al.
Mabs|January 13, 2010
Preclinical development of monoclonal antibodies: considerations for the use of non-human primatesKathryn Chapman, Nick Pullen, Lee Coney, et al.
Mabs|January 13, 2010
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemiaMay Kung Sutherland, Changpu Yu, Timothy S Lewis, et al.
Mabs|January 13, 2010
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41Donna L Montgomery, Ying-Jie Wang, Renee Hrin, et al.
Mabs|January 14, 2010
Charge-based analysis of antibodies with engineered cysteines: from multiple peaks to a single main peakXiaoying Nancy Chen, Mary Nguyen, Fred Jacobson, et al.
Mabs|January 14, 2010
Probabilities of success for antibody therapeuticsJanice M Reichert
Mabs|January 14, 2010
Antibody-maytansinoid conjugates for the treatment of myelomaRobert J Lutz, Kathleen R Whiteman
Mabs|January 14, 2010
Guardians at the gate: patent protection for therapeutic monoclonal antibodies--part 1Kevin W McCabe
Pageof 184